ADReCS

Pharmaceutical Information

Drug Name	Acetylcysteine
Drug ID	BADD_D00032
Description	Acetylcysteine is an antioxidant and glutathione inducer indicated for mucolytic therapy and the treatment of [acetaminophen] overdose.[L31378,L31383,L31388,L31478] Acetylcysteine has also been studied for a wide variety of off-label indications with mixed results.[A228158,A228163,A228168] Acetylcysteine was granted FDA approval on 14 September 1963.[L31488]
Indications and Usage	Acetylcysteine is indicated for mucolytic therapy and in the management of [acetaminophen] overdose.[L31378,L31383,L31388,L31478]
Marketing Status	approved; investigational
ATC Code	R05CB01; S01XA08; V03AB23
DrugBank ID	DB06151
KEGG ID	D00221
MeSH ID	D000111
PubChem ID	12035
TTD Drug ID	D06XGW
NDC Product Code	70594-111; 12598-7311; 49452-0098; 51552-0201; 51927-1601; 63323-694; 70710-1015; 55150-259; 66220-207; 0517-7610; 55154-5731; 12598-7302; 12598-7308; 12598-7323; 14445-412; 63323-963; 0409-3307; 0517-7504; 0517-7630; 72611-860; 83270-001; 25021-812; 63323-693; 63323-695; 0409-3308; 0517-7604; 17478-660; 63323-690; 63323-692; 0517-7510; 70771-1412; 52932-0704; 63323-691; 12598-7027; 52951-001; 0574-0805; 12598-7294; 12598-7327; 52133-0002; 52932-0742; 55154-5730
UNII	WYQ7N0BPYC
Synonyms	Acetylcysteine \| N-Acetyl-L-cysteine \| N Acetyl L cysteine \| N-Acetylcysteine \| N Acetylcysteine \| Mercapturic Acid \| Acid, Mercapturic \| Solmucol \| Genac \| Acemuc \| Acetabs \| Acetylcystein AL \| NAC AL \| Acetylcystein Atid \| Acetylcystein Heumann \| Acetylcystein Trom \| Acetylcysteine Hydrochloride \| Hydrochloride, Acetylcysteine \| Acetylcysteine Sodium \| Sodium, Acetylcysteine \| Acetylcysteine, Monosodium Salt \| Monosodium Salt Acetylcysteine \| Acetylcysteine Zinc \| Zinc, Acetylcysteine \| Acetylcysteine, (D)-Isomer \| Acetylcysteine, (DL)-Isomer \| Acetylcysteine, Monoammonium Salt \| Monoammonium Salt Acetylcysteine \| Acetyst \| Acétylcystéine GNR \| Airbron \| Alveolex \| Bromuc \| Azubronchin \| Bisolvon NAC \| NAC, Bisolvon \| Broncho-Fips \| Broncho Fips \| BronchoFips \| Broncholysin \| Broncoclar \| Codotussyl \| Cystamucil \| Dampo Mucopect \| Mucopect, Dampo \| durabronchal \| Larylin NAC \| Eurespiran \| Exomuc \| Fluimucil \| NAC Zambon \| Zambon, NAC \| Fabrol \| Fluprowit \| Optipect Hustengetränk \| Hustengetränk, Optipect \| Muco Sanigen \| Sanigen, Muco \| Frekatuss \| Jenacystein \| Jenapharm \| Lantamed \| Lindocetyl \| M-Pectil \| M Pectil \| MPectil \| mentopin Acetylcystein \| Acetylcystein, mentopin \| Muciteran \| Mucomyst \| Acetylin \| Mucosil \| Mucosol \| Mucosolvin \| Siccoral \| Siran \| Ilube \| Hoestil \| acebraus

Chemical Information

Molecular Formula	C5H9NO3S
CAS Registry Number	616-91-1
SMILES	CC(=O)NC(CS)C(=O)O
Chemical Structure

ADRs Induced by Drug

*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.

ADR Term	ADReCS ID	ADR Frequency (FAERS)	ADR Severity Grade (FAERS)	ADR Severity Grade (CTCAE)
Urticaria	10.01.06.001; 23.04.02.001	0.000402%
Ventricular fibrillation	02.03.04.008	0.000149%
Vomiting	07.01.07.003	0.000997%
Wheezing	22.03.01.009	0.000149%
Brain oedema	12.01.10.010; 17.07.02.003	0.000223%
General physical health deterioration	08.01.03.018	0.000223%		-
Sticky skin	23.03.03.019	-	-	-
Ear discomfort	04.03.01.005	0.000149%		-
Toxic skin eruption	10.01.01.008; 12.03.01.073; 23.03.05.003	0.000223%		-
Angiopathy	24.03.02.007	-	-	-
Cardiac disorder	02.11.01.003	-	-	-
Inflammation	08.01.05.007; 10.02.01.089	0.000521%		-
Mediastinal disorder	22.09.03.001	-	-	-
Inner ear disorder	04.04.02.002	-	-	-
Tympanic membrane disorder	04.05.04.002	0.000298%		-
Renal impairment	20.01.03.010	0.000446%		-
Bronchial secretion retention	22.03.02.008	-	-	-
Hypertransaminasaemia	09.01.02.005	0.000149%		-
Sensitisation	08.01.05.009; 10.02.01.012	-	-	-
Drug-induced liver injury	09.01.07.023; 12.03.01.044	0.000149%		-
Middle ear inflammation	04.05.01.006	0.000298%
Administration site extravasation	08.02.04.019; 12.07.04.019	0.000327%		-
Behaviour disorder	19.01.01.005	0.000149%		-
Drug ineffective for unapproved indication	08.06.01.038; 12.09.02.002	0.000298%		-
Swelling of eyelid	06.04.04.018; 10.01.05.026; 23.04.01.026	0.000506%		-

The 5th Page First Pre 5 Total 5 Pages